We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer/BioNTech’s BLA Gets Priority Review Designation From FDA
Pfizer/BioNTech’s BLA Gets Priority Review Designation From FDA
The FDA has granted priority review designation to Pfizer’s and BioNTech’s Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in people 16 years of older.